{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"91.1","upperLimit":"99.4","value":"97.7"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"91.1","upperLimit":"99.4","value":"97.7"}]}],"title":"18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89.6","upperLimit":"98.9","value":"96.5"}]}],"title":"24 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"87.5","upperLimit":"98.2","value":"95.1"}]}],"title":"36 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"87.5","upperLimit":"98.2","value":"95.1"}]}],"title":"48 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.0","upperLimit":"95.2","value":"90.1"}]}],"title":"60 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"}],"units":"Participants"}],"description":"Recurrence-free survival (RFS) assessment is based on the radiologic evidence and is defined as the time from the date of first dose of imatinib to the date of the first documented disease recurrence or death due to any cause (event). RFS estimates were summarized using the Kaplan-Meier product-limit method (Kaplan 1958). Censoring rules for RFS with the earliest occurring rule used in the analysis: subjects without objective recurrence of disease who were alive at the time of their discontinuation from study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment and subjects recording antineoplastic therapy during the study were censored on the date of the therapy initiated","dispersionType":"95% Confidence Interval","groups":[{"description":"All subjects received in tablet form imatinib (STI571) 400 mg once daily.","id":"OG000","title":"Imatinib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline up to 60 months","title":"Kaplan-Meier Estimates for Recurrence-free Survival up to 60 Months","type":"PRIMARY","unitOfMeasure":"percentage of patients"}